Cited by 132Transplantation: Methods and OutcomesTelomeres, Telomerase, and SenescenceInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post–lung transplantation survival

Open access
Newton, Chad A., Kozlitina, Julia, Lines, Jefferson R., Kaza, Vaidehi, Torres, Fernando, Garcia, Christine Kim·2017·The Journal of Heart and Lung Transplantation

Abstract

Background Prior studies have shown that patients with pulmonary fibrosis with mutations in the telomerase genes have a high rate of certain complications after lung transplantation. However, few studies have investigated clinical outcomes by leukocyte telomere length. Methods We conducted an observational cohort study of all pulmonary fibrosis patients who underwent lung transplantation at a single center between January 1, 2007 and December 31, 2014. Leukocyte telomere length was measured from a sample of blood collected prior to lung transplantation and subjects were stratified into two groups (telomere length <10th versus ≥10th percentile). The primary outcome was post-lung transplant survival. Secondary outcomes included incidence of allograft dysfunction, non-pulmonary organ dysfunction and infection. Results Approximately one-third (32%) of subjects had a telomere length below the 10th percentile. Telomere length <10th percentile was independently associated with worse survival (HR 10.9, 95% CI 2.7–44.8, p=0.001). Telomere length <10th percentile was also independently associated with a shorter time to the onset of chronic lung allograft dysfunction (CLAD) (HR 6.3, 95% CI 2.0–20.0, p=0.002). Grade 3 primary graft dysfunction occurred more frequently in the <10th percentile group compared to the ≥10th percentile group (28% vs 7%, p=0.034). There was no difference in the incidence of acute cellular rejection, cytopenias, infection or renal dysfunction in the two groups. Conclusions Telomere length <10th percentile was associated with worse survival and shorter time to onset of CLAD, and thus represents a biomarker that may aid in the risk stratification of pulmonary fibrosis patients prior to lung transplantation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.healun.2017.02.005

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In independent cohorts, shorter telomere length is a robust independent predictor of disease progression, response to therapy and death in IPF, and is associated with shorter time to allograft dysfunction after lung transplant.

    “In independent cohorts, a shorter telomere length was demonstrated to be a robust independent predictor of disease progression, response to therapy and death55, and to be associated with a shorter time to allograft dysfunction following lung transplant56.”

    From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [56]

    Experimental — accuracy not yet measured
  • In interstitial lung diseases needing special consideration, possible extrapulmonary involvement can complicate transplant assessment and acceptance.

    “Transplant challenges in these patients relate to potential extrapulmonary involvement which may complicate assessment and acceptance for transplant.(38, 238, 239)”

    From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [238]

    The Introduction mentions rigorous pre-transplant evaluation and selection, and the Results section on other manifestations of organ dysfunction reports non-pulmonary problems after transplantation. Neither passage says that potential extrapulmonary involvement complicates assessment or acceptance for transplantation. Searches for extrapulmonary involvement, transplant candidacy, and pre-transplant evaluation found no passage addressing that link. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Newton, C. A., Kozlitina, J., Lines, J. R., Kaza, V., Torres, F., & Garcia, C. K.
Affiliations
The University of Texas Southwestern Medical Center (US)
Corresponding author
Garcia, Christine Kim
Venue
The Journal of Heart and Lung Transplantation
Publisher
Elsevier BV
Published
2017-08
Volume
36
Issue
8
Pages
845-853
ISSN
1053-2498 (ISSN-L)
OpenAlex
W2585224414
Cited by
132
References
49
Citations by year
2026: 12 · 2025: 19 · 2024: 10 · 2023: 15 · 2022: 16 · 2021: 17 · 2020: 12 · 2019: 15 · 2018: 14 · 2017: 2
FWCI
12.04
Type
journal article
Language
en
Open access
Locations
  • The Journal of Heart and Lung Transplantation (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (UL1TR001105)
  • National Heart, Lung, and Blood Institute (R01HL093096, T32HL098040)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Keywords
telomere length, pulmonary fibrosis, lung transplantation, chronic lung allograft dysfunction, post-transplant survival, leukocyte telomere length, telomerase mutations, primary graft dysfunction, acute cellular rejection, risk stratification, biomarkers
MeSH terms
Chronic Disease, DNA, Female, Follow-Up Studies, Graft Survival, Humans, Male, Middle Aged, Postoperative Complications, Postoperative Period, Prospective Studies, Pulmonary Fibrosis, Risk Factors, Texas, Incidence, Survival Rate, Lung Transplantation, Polymerase Chain Reaction, Telomere, Primary Graft Dysfunction, Telomere Homeostasis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review